Compare Aurobindo Pharma with STRIDES PHARMA SCIENCE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs STRIDES PHARMA SCIENCE - Comparison Results

AUROBINDO PHARMA     Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

STRIDES PHARMA SCIENCE 
   Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AUROBINDO PHARMA STRIDES PHARMA SCIENCE AUROBINDO PHARMA/
STRIDES PHARMA SCIENCE
 
P/E (TTM) x 18.7 20.8 89.8% View Chart
P/BV x 3.8 1.3 299.9% View Chart
Dividend Yield % 0.3 0.4 72.3%  

Financials

 AUROBINDO PHARMA   STRIDES PHARMA SCIENCE
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-19
STRIDES PHARMA SCIENCE
Mar-18
AUROBINDO PHARMA/
STRIDES PHARMA SCIENCE
5-Yr Chart
Click to enlarge
High Rs8301,147 72.4%   
Low Rs527642 82.1%   
Sales per share (Unadj.) Rs333.9317.2 105.2%  
Earnings per share (Unadj.) Rs40.47.8 514.4%  
Cash flow per share (Unadj.) Rs51.825.1 206.6%  
Dividends per share (Unadj.) Rs2.502.00 125.0%  
Dividend yield (eoy) %0.40.2 164.8%  
Book value per share (Unadj.) Rs237.1274.3 86.4%  
Shares outstanding (eoy) m585.9189.50 654.6%   
Bonus/Rights/Conversions ESOPESOP-  
Price / Sales ratio x2.02.8 72.1%   
Avg P/E ratio x16.8114.0 14.7%  
P/CF ratio (eoy) x13.135.7 36.7%  
Price / Book Value ratio x2.93.3 87.8%  
Dividend payout %6.225.5 24.3%   
Avg Mkt Cap Rs m397,56980,058 496.6%   
No. of employees `00017.92.5 712.2%   
Total wages/salary Rs m25,8494,341 595.5%   
Avg. sales/employee Rs Th10,956.911,325.8 96.7%   
Avg. wages/employee Rs Th1,447.71,731.4 83.6%   
Avg. net profit/employee Rs Th1,324.3280.1 472.9%   
INCOME DATA
Net Sales Rs m195,63628,394 689.0%  
Other income Rs m1,553941 165.1%   
Total revenues Rs m197,18929,334 672.2%   
Gross profit Rs m39,5193,965 996.6%  
Depreciation Rs m6,6801,540 433.6%   
Interest Rs m2,6261,962 133.8%   
Profit before tax Rs m31,7671,403 2,263.9%   
Minority Interest Rs m270-   
Prior Period Items Rs m0-168 0.0%   
Extraordinary Inc (Exp) Rs m-881-436 202.1%   
Tax Rs m7,26997 7,470.2%   
Profit after tax Rs m23,645702 3,367.8%  
Gross profit margin %20.214.0 144.6%  
Effective tax rate %22.96.9 330.0%   
Net profit margin %12.12.5 488.8%  
BALANCE SHEET DATA
Current assets Rs m153,64524,836 618.6%   
Current liabilities Rs m120,42918,993 634.1%   
Net working cap to sales %17.020.6 82.5%  
Current ratio x1.31.3 97.6%  
Inventory Days Days13571 190.5%  
Debtors Days Days64113 56.2%  
Net fixed assets Rs m103,90934,289 303.0%   
Share capital Rs m586895 65.5%   
"Free" reserves Rs m138,32223,651 584.9%   
Net worth Rs m138,90824,546 565.9%   
Long term debt Rs m1,80015,513 11.6%   
Total assets Rs m264,54465,437 404.3%  
Interest coverage x13.11.7 763.7%   
Debt to equity ratio x00.6 2.0%  
Sales to assets ratio x0.70.4 170.4%   
Return on assets %9.94.1 243.9%  
Return on equity %17.02.9 595.1%  
Return on capital %23.86.9 345.7%  
Exports to sales %49.60-   
Imports to sales %18.80-   
Exports (fob) Rs m97,091NA-   
Imports (cif) Rs m36,741NA-   
Fx inflow Rs m97,31615,697 620.0%   
Fx outflow Rs m40,589735 5,519.3%   
Net fx Rs m56,72714,962 379.1%   
CASH FLOW
From Operations Rs m16,2201,871 867.1%  
From Investments Rs m-28,7685,826 -493.8%  
From Financial Activity Rs m19,191-10,157 -188.9%  
Net Cashflow Rs m6,656-2,615 -254.6%  

Share Holding

Indian Promoters % 54.1 27.7 195.3%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 8.0 37.8 21.0%  
FIIs % 27.7 8.6 322.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.2 25.9 39.4%  
Shareholders   69,601 56,241 123.8%  
Pledged promoter(s) holding % 8.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AUROBINDO PHARMA With:   SHASUN PHARMA  DR. REDDYS LAB  GSK PHARMA  FULFORD INDIA  WYETH LTD  

Compare AUROBINDO PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices End Flat; Power and Telecom Stocks Witness Buying(Closing)

Indian share markets witnessed volatile trading activity throughout the day today and ended on a flat note.

Related Views on News

DR. REDDYS LAB at All Time High; BSE HEALTHCARE Index Down 0.1% (Market Updates)

Aug 7, 2020 | Updated on Aug 7, 2020

DR. REDDYS LAB share price has hit an all time high at Rs 4,707 (up 0.7%). The BSE HEALTHCARE Index is down by 0.1%. Among the top gainers in the BSE HEALTHCARE Index today are DR. REDDYS LAB (up 0.7%) and ABBOTT INDIA (up 0.1%). The top losers include CIPLA (down 0.1%) and PFIZER (down 0.2%).

GRANULES INDIA at All Time High; BSE HEALTHCARE Index Up 0.6% (Market Updates)

Aug 7, 2020 | Updated on Aug 7, 2020

GRANULES INDIA share price has hit an all time high at Rs 329 (down 0.7%). The BSE HEALTHCARE Index is up by 0.6%. Among the top gainers in the BSE HEALTHCARE Index today are GRANULES INDIA (down 0.2%) and ABBOTT INDIA (up 0.2%). The top losers include J.B.CHEMICALS and SUN PHARMA ADV. RES. (down 0.1%).

AUROBINDO PHARMA Announces Quarterly Results (4QFY20); Net Profit Up 48.2% (Quarterly Result Update)

Jun 5, 2020 | Updated on Jun 5, 2020

For the quarter ended March 2020, AUROBINDO PHARMA has posted a net profit of Rs 9 bn (up 48.2% YoY). Sales on the other hand came in at Rs 62 bn (up 16.4% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 0.5% (Quarterly Result Update)

Feb 7, 2020 | Updated on Feb 7, 2020

For the quarter ended December 2019, AUROBINDO PHARMA has posted a net profit of Rs 7 bn (down 0.5% YoY). Sales on the other hand came in at Rs 58 bn (up 10.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 4.6% (Quarterly Result Update)

Nov 15, 2019 | Updated on Nov 15, 2019

For the quarter ended September 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 4.6% YoY). Sales on the other hand came in at Rs 56 bn (up 17.9% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

More Views on News

Most Popular

These 5 Smallcaps Deserve a Place in Your Coffee Can Portfolio(Profit Hunter)

Jul 28, 2020

When it comes to quality stocks, doing less is more.

Before You Buy Your First Electric Vehicle Consider Buying this Stock(Profit Hunter)

Jul 29, 2020

As competition intensifies in the electric vehicle space, only few will create huge wealth over the years.

How to Buy Gold and Silver(Fast Profits Daily)

Jul 27, 2020

In this video I'll show you how to buy bullion the right way.

Large Opportunities Are Coming Our Way

Aug 5, 2020

Kenneth Andrade tells us why stocks will bounce back strongly and what he's bullish on.

More

Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Aug 7, 2020 (Close)

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA 5-YR ANALYSIS

COMPARE AUROBINDO PHARMA WITH

MARKET STATS